We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Technology to Be Used in Visceral Leishmaniasis Diagnostic

By LabMedica International staff writers
Posted on 21 May 2009
Print article
Chromatographic immunoassay technology will be used in the development of a low-cost device for diagnosis of visceral Leishmaniasis.

The Infectious Disease Research Institute (IDRI; Seattle, WA, USA) and Chembio Diagnostics Systems, Inc. (New York, NY, USA) have entered into an agreement in which Chembio will use its dual path platform (DPP) based on chromatographic immunoassay technology and other Chembio capabilities to design, develop, and manufacture a low-cost device for the diagnosis of visceral leishmaniasis. The agreement was announced at the 96th annual meeting of the American Association of Immunologists (Immunology 2009) held May 8-12, 2009, in Seattle (WA, USA).

Most visceral Leishmaniasis cases occur in poor populations living in remote areas far from healthcare centers. In these settings, the disease often coexists with malaria and other debilitating parasitic infections that exhibit similar symptoms, making diagnosis difficult. Traditional labor-intensive and complex diagnostic procedures--invasive removal of bone marrow, spleen, and lymph node tissues for microscopic examination and isolation of the parasite by culture--are neither feasible nor field friendly.

"We are actively working to develop a rapid and simple test that could be used in the field in Africa to diagnose visceral Leishmaniasis by using no more than a drop of blood," said Dr. Steven Reed, founder and head of IDRI's Research and Development Program. "This would dramatically improve early detection of visceral Leishmaniasis, making current treatments more effective and decreasing transmission rates."

Visceral Leishmaniasis (VL) is a serious, potentially lethal, systemic parasitic illness that has caused epidemics in India, Southeast Asia, Africa, and Latin America. About 500,000 new cases of visceral Leishmaniasis occur each year, and 10% of these patients, mostly children, die because their disease cannot be accurately diagnosed in a timely fashion.

Related Links:

Infectious Disease Research Institute
Chembio Diagnostics Systems



New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Vitamin B12 Test
CHORUS CLIA VIT B12

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.